AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20189653 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal microscopy (CM) parameters: MGALD, MGASD, ICD, MGAUD
Number of subjects: 20
Study 20189653 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal microscopy (CM) parameters: MGALD
Number of subjects: 20
Study 20189653 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal microscopy (CM) parameters: MGASD
Number of subjects: 20
Study 20189653 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal microscopy (CM) parameters: ICD
Number of subjects: 20
Study 20189653 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal microscopy (CM) parameters: MGAUD
Number of subjects: 20
Study 17585021 — intervention group
Group type: EXPERIMENTAL
Intervention: High glucosinolate broccoli
Number of subjects: 16
Study 17585021 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard broccoli
Number of subjects: 16
Study 17585021 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 16
Study 15096570 — intervention group
Group type: EXPERIMENTAL
Intervention: Invader biplex assay
Number of subjects: 1448
Study 15096570 — intervention group
Group type: COMPARATOR
Intervention: PCR-based methods (AS-PCR, PCR-RFLP, PCR-mass spectrometry)
Number of subjects: 1448
Study 12043107 — intervention group
Group type: EXPERIMENTAL
Intervention: LCHP ketogenic diet
Number of subjects: 0
Study 12043107 — intervention group
Group type: EXPERIMENTAL
Intervention: Zone diet
Number of subjects: 0
Study 12043107 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hypocaloric diabetic exchange diet
Number of subjects: 0
Study 12043107 — intervention group
Group type: COMPARATOR
Intervention: Comparison across diet groups
Number of subjects: 0
Study 9829223 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid replacement therapy (L-thyroxine) for 3 months
Number of subjects: 23
Study 9829223 — intervention group
Group type: COMPARATOR
Intervention: Control group (46 sex- and age-matched healthy newborns)
Number of subjects: 23
Study 8160095 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radiation therapy (12.5 Gy total dose over 5 days with 2.5 Gy per day)
Number of subjects: 24
Study 8160095 — intervention group
Group type: COMPARATOR
Intervention: Stent implantation alone (no radiation therapy)
Number of subjects: 24
Study 2808308 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 48
Study 2808308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 48
Study 2808308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 1096537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium sulphate (24 mmol) after a standardized meal
Number of subjects: 30
Study 1096537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium sulphate (24 mmol) on an empty stomach
Number of subjects: 30
Study 1096537 — intervention group
Group type: COMPARATOR
Intervention: Lithium citrate in slow release tablets
Number of subjects: 30
Study 1096537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30783682 — intervention group
Group type: EXPERIMENTAL
Intervention: Vatelizumab (monoclonal antibody targeting α2 subunit of VLA-2)
Number of subjects: 0
Study 30783682 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29260225 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFields plus maintenance temozolomide (n=466)
Number of subjects: 695
Study 29260225 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide alone (n=229)
Number of subjects: 695
Study 26006137 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative statin therapy (atorvastatin 40 mg per day starting 6 hours after operation)
Number of subjects: 60
Study 26006137 — intervention group
Group type: COMPARATOR
Intervention: Non-statin group (no postoperative statin therapy)
Number of subjects: 60
Study 26006137 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative atorvastatin
Number of subjects: 60
Study 26006137 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a predictor
Number of subjects: 60
Study 23675788 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month jump-landing training program
Number of subjects: 243
Study 21627686 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose angiotensin receptor blockers
Number of subjects: 1051
Study 21627686 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose angiotensin receptor blockers
Number of subjects: 1051
Study 19320697 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised Advice‐giving; combination of 'Information Management' activities and 'Interactive Orientation'
Number of subjects: 106
Study 16764345 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levocarnitine, 3-6 g daily
Number of subjects: 0
Study 16764345 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive or immunomodulatory therapies
Number of subjects: 0
Study 15168381 — intervention group
Group type: EXPERIMENTAL
Intervention: URR greater-than-75%
Number of subjects: 74120
Study 15168381 — intervention group
Group type: COMPARATOR
Intervention: URR 70%-to-75%
Number of subjects: 74120
Study 15168381 — intervention group
Group type: EXPERIMENTAL
Intervention: URR > or = 65%
Number of subjects: 74120
Study 11327064 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (160 mJ/pulse, 10 Hz)
Number of subjects: 20
Study 11327064 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 20
Study 9470829 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma 4 million units (0.2 mg) subcutaneously every other day for 4 months
Number of subjects: 120
Study 9470829 — intervention group
Group type: COMPARATOR
Intervention: Observation (no maintenance therapy)
Number of subjects: 120
Study 9470829 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma
Number of subjects: 120
Study 7895954 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (blood glucose 2.5 mmol/l) with 90 degrees headup posture
Number of subjects: 10
Study 7895954 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (blood glucose 2.5 mmol/l) with return to supine posture
Number of subjects: 10
Study 7895954 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (blood glucose 2.5 mmol/l) after 40 min
Number of subjects: 10
Study 7895954 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemia (blood glucose 5.0 mmol/l) using a hyperinsulinaemic clamp
Number of subjects: 10
Study 7895954 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing maintained during hypoglycaemia
Number of subjects: 10
Study 2879101 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram dose of Merck, Sharp and Dohme plasma vaccine
Number of subjects: 119
Study 2879101 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms dose of Merck, Sharp and Dohme plasma vaccine
Number of subjects: 119
Study 2879101 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 2 micrograms doses of vaccine
Number of subjects: 119
Study 31318424 — intervention group
Group type: EXPERIMENTAL
Intervention: Serologic testing for anti-measles virus IgG antibody in a subsample of survey participants.
Number of subjects: 0
Study 31318424 — intervention group
Group type: COMPARATOR
Intervention: Standard estimate based on positive recall or HBR documentation.
Number of subjects: 0
Study 27241450 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1250 pulses at 10 Hz for 10 sessions over 2 weeks)
Number of subjects: 12
Study 27241450 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (n=6)
Number of subjects: 12
Study 25774645 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with everolimus-eluting stents
Number of subjects: 880
Study 25774645 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 880
Study 24128322 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) plus adjuvant systemic therapy
Number of subjects: 86
Study 24128322 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant systemic therapy alone (Control)
Number of subjects: 86
Study 24128322 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent DTC 12 months after diagnosis
Number of subjects: 86
Study 21271803 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional adaptive directional hearing aid
Number of subjects: 21
Study 21271803 — intervention group
Group type: COMPARATOR
Intervention: Omnidirectional hearing aid
Number of subjects: 21
Study 21271803 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive directional with anti-cardioid algorithm
Number of subjects: 21
Study 19269753 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC BNO 1095 extract (40mg herbal drug)
Number of subjects: 217
Study 19269753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 16763787 — intervention group
Group type: EXPERIMENTAL
Intervention: Anvirzel (0.1, 0.2, 0.4, 0.8, 1.2 ml/m2/day)
Number of subjects: 18
Study 12783047 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E (Caffeine 4 mg x kg‐1 + Ephedrine 0.8 mg x kg‐1)
Number of subjects: 13
Study 12783047 — intervention group
Group type: EXPERIMENTAL
Intervention: E (Ephedrine 0.8 mg x kg‐1)
Number of subjects: 13
Study 12783047 — intervention group
Group type: COMPARATOR
Intervention: C (Caffeine 4 mg x kg‐1)
Number of subjects: 13
Study 12783047 — intervention group
Group type: COMPARATOR
Intervention: P (Placebo)
Number of subjects: 13
Study 12783047 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E and E (combined)
Number of subjects: 13
Study 12783047 — intervention group
Group type: COMPARATOR
Intervention: C (Caffeine) and P (Placebo)
Number of subjects: 13
Study 11049012 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 10
Study 11049012 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 9323668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dodecafluoropentane
Number of subjects: 20
Study 9323668 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 20
Study 8378743 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 9
Study 8378743 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study 3758239 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuhaler (terbutaline 0.10 mg/kg)
Number of subjects: 21
Study 3758239 — intervention group
Group type: COMPARATOR
Intervention: Nebulizer (terbutaline 0.10 mg/kg)
Number of subjects: 21
Study 3758239 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuhaler
Number of subjects: 21
Study 3758239 — intervention group
Group type: COMPARATOR
Intervention: Nebulizer
Number of subjects: 21
Study 28757316 — intervention group
Group type: EXPERIMENTAL
Intervention: WATS in conjunction with biopsy sampling
Number of subjects: 160
Study 28757316 — intervention group
Group type: COMPARATOR
Intervention: Biopsy sampling alone
Number of subjects: 160
Study 27031862 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupressure
Number of subjects: 150
Study 27031862 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 150
Study 27031862 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 24089509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group with a 50% higher stimulated C-peptide on entry (from 0.10 to 0.15 nmol/L)
Number of subjects: 0
Study 24089509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group with a 50% higher stimulated C-peptide on entry
Number of subjects: 0
Study 22789125 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (12.5mg to 50mg daily)
Number of subjects: 37
Study 22789125 — intervention group
Group type: COMPARATOR
Intervention: Control group (unexposed to TPR‐A)
Number of subjects: 37
Study 20429948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up
Number of subjects: 299
Study 20429948 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospital follow-up
Number of subjects: 299
Study 18515595 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian group
Number of subjects: 83
Study 18515595 — intervention group
Group type: COMPARATOR
Intervention: African American group
Number of subjects: 83
Study 18515595 — intervention group
Group type: EXPERIMENTAL
Intervention: Male group
Number of subjects: 83
Study 18515595 — intervention group
Group type: COMPARATOR
Intervention: Female group
Number of subjects: 83
Study 16518002 — intervention group
Group type: COMPARATOR
Intervention: Once daily dosing (ODD) - 160 mg once daily
Number of subjects: 52
Study 16518002 — intervention group
Group type: COMPARATOR
Intervention: Pharmacokinetic dosing (TCI) - 160 mg once daily initially, dose revised based on serum drug levels
Number of subjects: 52
Study 16518002 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (CG) - 80 mg gentamicin twice daily
Number of subjects: 52
Study 12818938 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin Lift (CL)
Number of subjects: 16
Study 12818938 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw Thrust (JT)
Number of subjects: 16
Study 12818938 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at 5 cm H(2)O with JT
Number of subjects: 16
Study 12818938 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no intervention)
Number of subjects: 16
Study 12439841 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg orally twice daily on the day before and the day of contrast administration with hydration
Number of subjects: 100
Study 12439841 — intervention group
Group type: COMPARATOR
Intervention: Control group with hydration protocol using hypotonic saline
Number of subjects: 100
Study 12439841 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) in patients with mild renal failure
Number of subjects: 100
Study 12439841 — intervention group
Group type: COMPARATOR
Intervention: Control group in patients with mild renal failure
Number of subjects: 100
Study 12439841 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) and control group
Number of subjects: 100
Study 9719082 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 0.20 g/m2
Number of subjects: 0
Study 9719082 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 0.40 g/m2
Number of subjects: 0
Study 9719082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9719082 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO (all doses)
Number of subjects: 0
Study 9719082 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO (0.20 g/m2 and 0.40 g/m2)
Number of subjects: 0
Study 7868408 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 299
Study 7868408 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin/clavulanate
Number of subjects: 299
Study 2582668 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression and grafting with electrical stimulation
Number of subjects: 116
Study 2582668 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression and grafting without electrical stimulation
Number of subjects: 116
Study 2582668 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 116
Study 4919027 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-DOPA
Number of subjects: 23
Study 4919027 — intervention group
Group type: COMPARATOR
Intervention: Standard agents
Number of subjects: 23
Study 4919027 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of drugs
Number of subjects: 23
Study 4919027 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 23
Study 30601228 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 6190
Study 30601228 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 6190
Study 28161927 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin eye drops for 1 day (6 times/d)
Number of subjects: 209
Study 28161927 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin eye drops for 2 days (3 times/d)
Number of subjects: 209
Study 28161927 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin eye drops for 3 days (3 times/d)
Number of subjects: 209
Study 28161927 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 209
Study 25989732 — intervention group
Group type: EXPERIMENTAL
Intervention: FAHT cream
Number of subjects: 233
Study 25989732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 23884317 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress Tolerance (DT) treatment (9 2-hr group and 6 50-min individual sessions) plus 8 weeks of transdermal nicotine patch
Number of subjects: 49
Study 23884317 — intervention group
Group type: COMPARATOR
Intervention: Standard Smoking Treatment (ST) (6 90-min group and 1 20-min individual session) plus 8 weeks of transdermal nicotine patch
Number of subjects: 49
Study 23884317 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress Tolerance (DT) treatment
Number of subjects: 49
Study 21854342 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate delivered via dry powder inhaler (MF-DPI) 100 μg once daily in the morning (QD AM)
Number of subjects: 187
Study 21854342 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate delivered via dry powder inhaler (MF-DPI) 100 μg twice daily (BID)
Number of subjects: 187
Study 21854342 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate delivered via dry powder inhaler (MF-DPI) 200 μg once daily in the morning (QD AM)
Number of subjects: 187
Study 21854342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 19394468 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular soda consumption
Number of subjects: 145
Study 19394468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-food restaurant use
Number of subjects: 145
Study 19394468 — intervention group
Group type: COMPARATOR
Intervention: Sugar-sweetened beverages consumption
Number of subjects: 145
Study 19394468 — intervention group
Group type: COMPARATOR
Intervention: High-fat foods consumption
Number of subjects: 145
Study 19394468 — intervention group
Group type: COMPARATOR
Intervention: Fast-food restaurant use frequency
Number of subjects: 145
Study 19394468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit/vegetable intake
Number of subjects: 145
Study 19394468 — intervention group
Group type: COMPARATOR
Intervention: Regular soda consumption and socioeconomic status
Number of subjects: 145
Study 16567155 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein (3.6 g/kg/day)
Number of subjects: 5
Study 16567155 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein (1.8 g/kg/day)
Number of subjects: 5
Study 16567155 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein (0.8 g/kg/day)
Number of subjects: 5
Study 16567155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake and fluid balance
Number of subjects: 5
Study 12507714 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release morphine given 4-hourly
Number of subjects: 40
Study 12507714 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release morphine given once daily
Number of subjects: 40
Study 10844490 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg i.m.
Number of subjects: 25
Study 10844490 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine 50 mg i.m.
Number of subjects: 25
Study 9117221 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% glycine
Number of subjects: 77
Study 9117221 — intervention group
Group type: COMPARATOR
Intervention: 1.5% glycine
Number of subjects: 77
Study 9117221 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ethanol
Number of subjects: 77
Study 8229755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (0, 12.5, 25 and 50 mg, i.v.)
Number of subjects: 8
Study 8229755 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (0, 1 and 2 mg given orally 2 hr before the cocaine injection)
Number of subjects: 8
Study 8229755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine + Mazindol
Number of subjects: 8
Study 8229755 — intervention group
Group type: COMPARATOR
Intervention: Cocaine alone
Number of subjects: 8
Study 30246320 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled procaterol
Number of subjects: 37
Study 30246320 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 37
Study 27232900 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing Etafilcon A contact lenses
Number of subjects: 30
Study 27232900 — intervention group
Group type: COMPARATOR
Intervention: No lens wear
Number of subjects: 30
Study 27232900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stages (lens wear and no lens wear)
Number of subjects: 30
Study 24141472 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel pressure measurements during polysomnography (PSG) on one night
Number of subjects: 51
Study 24141472 — intervention group
Group type: COMPARATOR
Intervention: Standard polysomnography (PSG) without pressure measurements on the other night
Number of subjects: 51
Study 22322921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive reinforced DE-PLAN intervention (n = 333)
Number of subjects: 2054
Study 22322921 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 219)
Number of subjects: 2054
Study 22322921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 2054
Study 20189465 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 67
Study 18719756 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises
Number of subjects: 118
Study 18719756 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 118
Study 18719756 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cones
Number of subjects: 118
Study 18719756 — intervention group
Group type: COMPARATOR
Intervention: No active treatment (control)
Number of subjects: 118
Study 15821318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerasorbe
Number of subjects: 127
Study 15821318 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study 12427202 — intervention group
Group type: EXPERIMENTAL
Intervention: Button-bracket splint (BS)
Number of subjects: 10